Abstract:Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is adapting to continuous presence in humans. Transitions to endemic infection patterns are associated with changes in the spike (S) proteins that direct virus-cell entry. These changes generate antigenic drift and thereby allow virus maintenance in the face of prevalent human antiviral antibodies. These changes also fine tune virus-cell entry dynamics in ways that optimize transmission and infection into human cells. Focusing on the latter aspect, we evaluated the effects of several S protein substitutions on virus-cell membrane fusion, an essential final step in enveloped virus-cell entry. Membrane fusion is executed by integral-membrane "S2" domains, yet we found that substitutions in peripheral "S1" domains altered late-stage fusion dynamics, consistent with S1-S2 heterodimers cooperating throughout cell entry. A specific H655Y change in S1 stabilized a fusion-intermediate S protein conformation and thereby delayed membrane fusion. The H655Y change also sensitized viruses to neutralization by S2-targeting fusion-inhibitory peptides and stem-helix antibodies. The antibodies did not interfere with early fusion-activating steps; rather they targeted the latest stages of S2-directed membrane fusion in a novel neutralization mechanism. These findings demonstrate that single amino acid substitutions in the S proteins both reset viral entry—fusion kinetics and increase sensitivity to antibody neutralization. The results exemplify how selective forces driving SARS-CoV-2 fitness and antibody evasion operate together to shape SARS-CoV-2 evolution. Most adaptive mutations endowing SARS-CoV-2 with increased human transmissibility and infectivity alter viral spike (S) protein structure and function. Orchestrated structural transitions in these multidomain S proteins mediate cell entry functions. Comparative analyses of adapted SARS-CoV-2 variants identified S domains conducting the rhythm of these transitions. The S1 adaptation H655Y slowed late virus-cell membrane fusion, revealing S1 as a timer for this essential and final cell entry event. The H655Y-directed delay left viruses vulnerable to neutralizing antibodies that target transitional fusion intermediate S conformations. Our findings highlight how mechanistic understandings of S protein structural dynamics illuminate antibody neutralization mechanisms and suggest that SARS-CoV-2 evolutionary pathways are shaped by competing selective pressures to optimize cell entry kinetics and evade neutralizing antibodies.

COVID-19 Serum Drives Spike-Mediated SARS-CoV-2 Variation

The Challenge of Emerging SARS-CoV-2 Mutants to Vaccine Development

Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunity

Crucial Mutations of Spike Protein on SARS-CoV-2 Evolved to Variant Strains Escaping Neutralization of Convalescent Plasmas and RBD-Specific Monoclonal Antibodies

Key mutations in the spike protein of SARS‐CoV‐2 affecting neutralization resistance and viral internalization

The evolution of the mechanisms of SARS-CoV-2 evolution revealing vaccine-resistant mutations in Europe and America

Spike mutations in SARS-CoV-2 variants confer resistance to antibody neutralization

Predicting the immune escape of SARS-CoV-2 neutralizing antibodies upon mutation

Altered spike dynamics drives immune evasion of SARS-CoV-2

Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization

Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion

Acquisition of resistance to wild-type spike-immune sera by emerging SARS-CoV-2 variants

Mutations of SARS-CoV-2 Spike Protein: Implications on Immune Evasion and Vaccine-Induced Immunity

SARS-CoV-2 Omicron variations reveal mechanisms controlling cell entry dynamics and antibody neutralization

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455–456 synergistically enhances antibody evasion and ACE2 binding

Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization

Distinct Patterns of SARS-CoV-2 BA.2.87.1 and JN.1 Variants in Immune Evasion, Antigenicity and Cell-Cell Fusion

SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape

Recurrent SARS-CoV-2 mutations at Spike D796 evade antibodies from pre-Omicron convalescent and vaccinated subjects

SARS-CoV-2 variants, spike mutations and immune escape